¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"common ion effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • common iliac lymph node
    ¿Â¾ûµ¢¸²ÇÁÀý, ÃÑÀå°ñ¸²ÇÁÀý
  • common integument
    ¿ÜÇÇ
  • common interosseous artery
    ¿Â»À»çÀ̵¿¸Æ, ÃѰñ°£µ¿¸Æ
  • common nevus
    º¸Åë¸ð¹Ý
  • common opsonin
    Á¤»ó¿É¼Ò´Ñ
  • common palmar digital artery
    ¿Â¹Ù´ÚÂʼհ¡¶ôµ¿¸Æ, ÃÑÀåÃøÁöµ¿¸Æ
  • common palmar digital nerve
    ¿Â¹Ù´ÚÂʼհ¡¶ô½Å°æ, ÃѼöÀåÃøÁö½Å°æ
  • common peroneal nerve
    ¿ÂÁ¾¾Æ¸®½Å°æ, ÃѺñ°ñ½Å°æ
  • common plantar digital artery
    ¿Â¹Ù´ÚÂʹ߰¡¶ôµ¿¸Æ, ÃÑ̫̿Áöµ¿¸Æ
  • common plantar digital nerve
    ¿Â¹Ù´ÚÂʹ߰¡¶ô½Å°æ, ÃÑÁ·ÀúÃøÁö½Å°æ
  • common ratio
    °øºñ
  • common synovial sheath
    ¿ÂÀ±È°Áý
  • common tendinous ring
    ¿ÂÈûÁÙ°í¸®
  • common tendon
    ¿ÂÈûÁÙ, °øÅë°Ç
  • common treating facility
    °øµ¿Ã³¸®½Ã¼³
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • common integument
    ¿ÜÇÇ
  • common nevus
    º¸Åë¸ð¹Ý
  • common opsonin
    (¢¡normal opsonin) Á¤»ó¿É¼Ò´Ñ
  • common ratio
    °øºñ
  • common reaction
    Á¤»ó¹ÝÀÀ
  • common tendon
    °øÅëÈûÁÙ, °øÅë°Ç
  • common vehicle
    °øÅë¸Å°³Ã¼
  • common ventricle
    °øÅë½É½Ç, ´Ü½É½Ç
  • common wart
    (¢¡verruca vulgaris) º¸Åë»ç¸¶±Í
  • common bile duct
    ¿Â¾µ°³°ü, ÃÑ´ã°ü
  • common dorsal mesentery
    ¿ÂµîÂÊâÀÚ°£¸·
  • common duct exploration
    ¿Â¾µ°³°üŽ»ö¼ú, ÃÑ´ã°üŽ»ö¼ú
  • common duct stone
    ¿Â¾µ°³°üµ¹, ÃÑ´ã°ü°á¼®
  • common hepatic duct
    ¿Â°£°ü
  • common iliac node lymph
    ¿Â¾ûµ¢¸²ÇÁÀý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Purkinje effect
    Ǫ¸£Å°´Ï¿¡È¿°ú
  • RF antennae effect
    °íÁÖÆÄ ¾ÈÅ׳ª È¿°ú
  • Stiles-Crawford effect
    ½ºÅ¸ÀϽº-Å©·ÎÆ÷µåÈ¿°ú
  • T1 shortening effect
    T1 ´ÜÃà È¿°ú
  • T2 shortening effect
    T2 ´ÜÃà È¿°ú
  • Tyndall effect
    ƾ´ÞÈ¿°ú
  • additive effect
    ºÎ°¡È¿°ú
  • additive effect
    »ó°¡È¿°ú (ßÓÊ¥üùÍý)
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • air barrier effect
    °ø±â¸·È¿°ú(ÍöѨدüùÍý).
  • air gap effect
    °ø±â °£°Ý È¿°ú
  • allogeneic effect
    µ¿Á¾ÀÌÇüÈ¿°ú
  • analgesic effect
    ÁøÅëÈ¿°ú.
  • antagonistic effect
    ±æÇ×È¿°ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ion recombination
    À̿ Àç°áÇÕ
  • ion selective
    À̿¼±ÅÃ
  • ion selective electrode
    À̿¼±ÅÃÀü±Ø
  • ion tube
    À̿°ü(¡­Î·).
  • ion-exchange chromatography
    À̿±³È¯Å©·Î¸¶Åä±×·¡ÇÇ
  • ion-exchange membrane
    À̿±³È¯¸·
  • latex ion
    Ãø±¼.
  • liquid ion-exchangc membrane
    ¾×üÀÌ¿Â-±³È¯¸·
  • negative ion
    À½(ëä)ÀÌ¿Â.
  • paramagnetic ion
    »óÀÚ¼º ÀÌ¿Â
  • positive ion
    ¾ç(åÕ)ÀÌ¿Â.
  • superoxide ion
    °ú»êÈ­¹° À½ÀÌ¿Â(¡­ëä¡­)
  • bean common mosaic virus
    Äá¸ðÀÚÀÌÅ©¹ÙÀÌ·¯½º
  • choledochus =common bile duct
    ÃÑ´ã°ü.
  • choledochus =common bile duct
    ³»°ú,¼ÒÈ­ÃÑ´ã°ü.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ion filtration chromatography
    À̿¿©°ú(ÕëΦ) Å©·Î¸¶Åä±×·¡ÇÇ
  • ion induced dipole interaction
    "ÀÌ¿ÂÀ¯µµ(ë¯Óô) ½Ö±ØÀÚ(äªÐ¿í­), »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)"
  • ion pair
    À̿ ½Ö(äª)
  • ion pair chromatography
    À̿¦ Å©·Î¸¶Åä±×·¡ÇÇ
  • ion pairing
    À̿ ¦Áþ±â
  • ion pump
    À̿ ÆßǪ
  • ion retardation
    À̿ Áö¿¬(òÀæÅ)
  • ion selective electrode
    À̿¼±ÅÃ(àÔ÷É) Àü±Ø(ï³Ð¿)
  • ion-translocating antibiotics
    ÀÌ¿ÂÀüÀ§ Ç×»ýÁ¦(ï®êÈù÷ßæð¥)
  • low-energy ion scattering
    Àú(î¸)¿¡³ÊÁö À̿ºлê(ÝÂߤ)
  • lyate ion
    ¿ë¸Å(éÁØÚ) À½(ëä)ÀÌ¿Â
  • lyonium ion
    ¿ë¸Å(éÁØÚ)¾ç(åÕ)ÀÌ¿Â
  • mobile ion carrier
    À̵¿(ì¹ÔÑ)À̿¿î¹Ýü(ê¡Úæô÷)
  • moleculoar ion
    ºÐÀÚ(ÝÂí­)ÀÌ¿Â
  • oxonium ion
    ¿Á¼Ò´Ï¿ò ÀÌ¿Â
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • magnetization transfer effect
    ÀÚÈ­Àü´ÞÈ¿°ú
  • main effect
    ÁÖÀÛ¿ë
  • mass effect
    Á¾±«È¿°ú
  • misregistration effect
    ¿Àµî·ÏÈ¿°ú
  • oblique angle effect
    »ç°¢È¿°ú
  • paramagnetic susceptibility effect
    »óÀÚ¼ºÀÚ±âÈ­È¿°ú
  • partial volume effect
    ºÎºÐ¿ëÀûÈ¿°ú
  • phase shift effect
    À§»óº¯À§È¿°ú
  • photoelectric effect
    ±¤ÀüÈ¿°ú
  • piezoelectric effect
    ¾ÐÀüÈ¿°ú
  • radiation effect
    ¹æ»ç¼±È¿°ú
  • radio-frequency thermal effect
    °íÁÖÆÄ¿­È¿°ú
  • reverse piezoelectric effect
    ¿ª¾ÐÀüÈ¿°ú
  • RF antennae effect
    °íÁ֯ľÈÅ׳ªÈ¿°ú
  • shielding effect
    Â÷ÆóÈ¿°ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FU fecal urobilinogen; fetal urobilinogen; fluorouracil; follow-up; flux unit [ion]; fractional urinaly...
H+ hydrogen ion
[H+] hydrogen ion concentration
HEIS high-energy ion scattering
ICM inner cell mass; integrated conditional model; intercostal margin; International Confederation of Mi...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CORBA Common Object Request Broker Architecture
CPN Common Peroneal Nerve
CTC Common Toxicity Criteria
CVID Common Variable Immuno-Deficiency
CBDL Common bile duct ligation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adrenal suppressive effect
    ºÎ½Å ¾ïÁ¦ È¿°ú
  • air gap effect
    °ø±â °£°Ý È¿°ú
  • allogenic effect
    µ¿Á¾ ¼¼Æ÷ ¹ÝÀÀ È¿°ú
    µ¿Á¾ÀÇ ¸²ÇÁ°í¸¦ Åõ¿©ÇÔÀ¸·Î½á ºñƯÀÌÀûÀ¸·Î ¸é¿ª¹ÝÀÀÀÌ Áõ°¡µÇ±âµµ ÇÏ°í ¾ïÁ¦µÇ±âµµ ÇÏ´Â Çö»ó. Áõ°¡µÈ °æ¿ì¸¦ Á¤ÀÇ allogenic È¿°ú, ¾ïÁ¦µÈ °æ¿ì¸¦ ºÎÀÇ allogenic È¿°ú¶ó°í ÇÑ´Ù.
  • anticurare effect
    Ç×Å¥¶ó·¹ ÀÛ¿ë
  • antitussive effect
    ÁøÇØ È¿°ú
  • autonomic effect
    ÀÚÀ² ½Å°æ¼º È¿°ú, ÀÚÀ² ½Å°æ È¿°ú
  • balloning effect
    ÆØÃ¢ È¿°ú
  • Bernouilli effect
    º£¸£´©ÀÌ È¿°ú
  • biological effect
    »ý¹°ÇÐÀû È¿°ú
  • blanching effect
    Ç¥¹é È¿°ú
  • blocking effect
    Â÷´Ü È¿°ú
  • carriar effect
    ´ãü È¿°ú
    Ha
  • carry effect
    ¿î¹Ý È¿°ú
  • cavitation effect
    °øµ¿ È¿°ú
  • clasp knife effect
    Á¢´Â Ä® È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
ion selective electrode An electrode half cell, with a semi permeable membrane that is permeable only to a single ion. The electrical potential measured between this and a reference half cell (e.g. A calomel electrode) is thus the Nernst potential for the ion. Given that the solution filling the ion selective electrode is known, the activity (rather than concentration) of the ion in the unknown solution can be measured. Commercial ion selective electrodes frequently use a hydrophobic membrane containing an ionophore, such as valinomycin (for potassium) or monensin (for sodium). A pH electrode is made with a thin membrane of pH sensitive (i.e. Proton permeable) glass.
(18 Nov 1997)
ion-selective electrodes Electrodes which can be used to measure the concentration of particular ions in cells, tissues, or solutions.
(12 Dec 1998)
ion transport The movement of ions across energy-transducing cell membranes. Transport can be active or passive. Passive ion transport (facilitated diffusion) derives its energy from the concentration gradient of the ion itself and allows the transport of a single solute in one direction (uniport). Active ion transport is usually coupled to an energy-yielding chemical or photochemical reaction such as ATP hydrolysis. This form of primary active transport is called an ion pump. Secondary active transport utilises the voltage and ion gradients produced by the primary transport to drive the cotransport of other ions or molecules. These may be transported in the same (symport) or opposite (antiport) direction.
(12 Dec 1998)
oxonium ion <chemistry> A positively charged ion that is water with an additional hydrogen atom (H3O).
(09 Oct 1997)
tetraethylammonium ion A monovalent cation widely used in neurophysiology as a specific blocker of potassium channels. It is similar in size to the hydrated potassium ion and gets stuck (reversibly) in the channels.
(18 Nov 1997)
field ion microscope <instrument> Type of microscopy in which the specimen is illuminated with ions, often gallium ions, that are focussed electrostatically. The ions remove components of the specimen, lower atomic masses first. These are imaged and provide information on elemental distribution with a resolution of perhaps 30 nm.
(18 Nov 1997)
ligand gated ion channel A transmembrane ion channel whose permeability is increased by the binding of a specific ligand, typically a neurotransmitter at a chemical synapse. The permeability change is often drastic, such channels let through effectively no ions when shut, but allow passage at up to 10exp7 ions sexp 1 when a ligand is bound. Recently, the receptors for both acetylcholine and GABA have been found to share considerable sequence homology, implying that there may be a family of structurally related ligand gated ion channels.
(18 Nov 1997)
light-ion fusion <radiobiology> Light-Ion-Beam-Driven Inertial Confinement fusion, using beams of light ions driven at implosion targets. Pulsed-power driven accelerators are relatively efficient and cost-effective, but beam-focusing is a technical hurdle for this approach.
(09 Oct 1997)
carotid artery, common The two principal arteries supplying the structures of the head and neck. They ascend in the neck, one on each side, and at the level of the upper border of the thyroid cartilage, each divides into two branches, the external (carotid artery, external) and internal (carotid artery, internal) carotid arteries.
(12 Dec 1998)
migraine, common Migraine without aura. The most frequent type, accounting for about 80-85% of migraines. See migraine.
(12 Dec 1998)
cold, common A viral upper respiratory tract infection. A contagious illness caused by a number of different types of viruses. Because of the great number of viruses that can cause a cold, the body never builds up resistance (immune) against all of them. For this reason, colds are a frequent and recurring problem. In fact, preschool children average 9 colds a year; those in kindergarten, 12 colds a year; and adolescents and adults, 7 colds per year. Going out into the cold weather has no effect on the spread of a cold. Antibiotics do not help the common cold.
(12 Dec 1998)
common acute lymphoblastic leukaemia <haematology, oncology> A sub-type of acute lymphoblastic leukaemia affecting cells early in the B lymphocyte lineage which accounts for about 80% of all acute lymphoblastic leukaemia.
Origin: Gr. Haima = blood
(13 Nov 1997)
common antigen Cross reacting antigen (epitope), a common antigen that occurs in 2 or more different molecules/organisms.
Synonym: heterogenic enterobacterial antigen.
(05 Mar 2000)
common baldness Hair loss in women that may be associated with aging, hormones (androgens) or genetic predisposition. The pattern of baldness in women is different from that of men. In women there is thinning of the hair all over the scalp, but the frontal hairline is maintained. The hair loss is usually permanent. Treatment has been successful with topical minoxidil in some cases.
(27 Sep 1997)
common basal vein <anatomy, vein> The tributary to the inferior pulmonary vein (right and left) that receives blood from the superior and inferior basal veins.
Synonym: vena basalis communis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • packing effect
    °áÇÕ È¿°ú !
  • photoelectric effect
    ±¤ÀüÈ¿°ú
  • ram effect
    ·¥ È¿°ú(±â¼Ó)ÀÇ Áõ°¡¿¡ µû¶ó ÈíÀÔ±¸¿¡ À¯ÀԵǴ °ø±âÀÇ ¾Ð·ÂÀÌ Áõ°¡ÇÏ´Â È¿°ú) '
  • ratchet effect
    ´Ü¼ÓÀû È¿°ú 
  • ripple effect
    ÆÄ±Þ È¿°ú !
  • shot effect,the
    (Áø°ø°üÀÇ À½±Ø¿¡¼­ ¹æ»çµÇ´Â ¿­ÀüÀÚÀÇ)»êź È¿°ú ''
  • side effect
    ºÎÀÛ¿ë
  • skin effect
    (Á֯ļö ÀüµµÃ¼ÀÇ)Ç¥ÇÇ È¿°ú
  • stage effect
    ¹«´ë È¿°ú
  • tunnel effect
    ÅͳΠȿ°ú !
  • common
    °øÅëÀÇ,Åë»óÀÇ
  • common wealth
    ÁÖ, ¿¬¹æ
  • common-sense
    »ó½ÄÀûÀÎ
  • Common Era
    =CHRISTIAN ERA
  • common
    °øÅëÀÇ;°øµ¿ÀÇ;°øÀ¯ÀÇ;»çȸÀϹÝÀÇ;°øÁßÀÇ;°ø°øÀÇ;º¸ÅëÀÇ;¹ü»óÇÑ;ÈçÇÑ;¼­¹ÎÀÇ;Æò¹üÇÑ;Åë¼ÓÀûÀÎ;ºñ¼ÓÇÑ;¾ßºñÇÑ;ǰÀ§°¡ ¾ø´Â;°ø¾àÀÇ;Å뼺ÀÇ;Åë°ÝÀÇ;Á¾ÇÕ(°øÅë)ÀÇ;(¸¶À» µîÀÇ)°øÀ¯Áö;°ø¿ëÁö;°ø¿ø(¿ïŸ¸® ¾ø´Â Ȳ¹«Áö µî);(¸ñÃÊÁö µîÀÇ)°øÀ¯±Ç;¹Ì»ç Åë»ó¹®;=commons
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á